Paul Tran

Summary

Affiliation: Harvard School of Public Health
Country: USA

Publications

  1. ncbi Early postpartum pharmacokinetics of lopinavir initiated intrapartum in Thai women
    Tim R Cressey
    Harvard School of Public Health, Boston, Massachusetts, USA
    Antimicrob Agents Chemother 53:2189-91. 2009
  2. ncbi Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum
    Tim R Cressey
    Program for HIV Prevention and Treatment IRD URI 174, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand
    J Acquir Immune Defic Syndr 59:245-52. 2012
  3. ncbi Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1
    Tim R Cressey
    Harvard School of Public Health, Boston, MA, USA
    J Acquir Immune Defic Syndr 38:283-8. 2005
  4. ncbi Low-doses of indinavir boosted with ritonavir in HIV-infected Thai patients: pharmacokinetics, efficacy and tolerability
    Tim R Cressey
    Harvard School of Public Health, Harvard University, Boston, MA, USA
    J Antimicrob Chemother 55:1041-4. 2005
  5. ncbi Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: an update
    Tim R Cressey
    Harvard School of Public Health, Boston, MA, USA
    Infect Genet Evol 7:333-42. 2007
  6. ncbi Indinavir/ritonavir remains an important component of HAART for the treatment of HIV/AIDS, particularly in resource-limited settings
    Tim R Cressey
    Chiang Mai University, Program for HIV Prevention and Treatment PHPT IRD174, 29 7 8 Samlan Road, Soi 1 Prasing, Muang, Chiang Mai, 50205, Thailand
    Expert Opin Drug Metab Toxicol 3:347-61. 2007
  7. ncbi Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy
    Tim R Cressey
    Department of Medical Technology, Chiang Mai University, Thailand
    AIDS 24:2193-200. 2010
  8. ncbi Influence of body weight on achieving indinavir concentrations within its therapeutic window in HIV-infected Thai patients receiving indinavir boosted with ritonavir
    Tim R Cressey
    Program for HIV Prevention and Treatment IRD URI 174, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand
    Ther Drug Monit 33:25-31. 2011

Collaborators

  • Gonzague Jourdain
  • Marc Lallemant
  • Mark Mirochnick
  • Nicole Ngo-Giang-Huong
  • Pilaipan Puthavathana
  • Thanyawee Puthanakit
  • Nottasorn Plipat
  • Maureen Shannon
  • Sombat Thanprasertsuk
  • Deborah Hirt
  • Jean Marc Treluyer
  • Saik Urien
  • K Chokephaibulkit
  • L M Frenkel
  • Tim R Cressey
  • Chureeratana Bowonwatanuwong
  • Sinart Prommas
  • Prapap Yuthavisuthi
  • Dujrudee Chinwong
  • Kanchana Than-in-at
  • Yardpiron Taworn
  • Renoo Wongsrisai
  • Suriyan Tanasri
  • Prakit Yothipitak
  • Pra ornsuda Sukrakanchana
  • Suwalai Chalermpantmetagul
  • Ruethai Wongchai
  • Ken McIntosh
  • Luc Decker
  • Aksorn Lueanyod
  • Elizabeth Smith
  • Sophie Le Coeur
  • Sanupong Chailert
  • Pimpinun Punyati
  • Kanjana Yoddee
  • Tiwacha Thimakam
  • Patcharaporn Krueduangkam
  • Suporn Koetsawang
  • Borwornluck Changlor
  • Somrat Matchua
  • Jullapong Achalapong
  • Janjira Thonglo
  • Ubon Chanasit
  • Nantasak Chotivanich
  • Pisut Greetanukroh
  • Kessarin Chaisiri
  • Nusara Krapunpongsakul
  • Marina Thitathan
  • Edmund Capparelli
  • Prattana Leenasirimakul
  • Michel Tod
  • Suparat Kunkeaw
  • Yanling Huo
  • Pannee Sirivatanapa
  • Chanon Neungton
  • Alice Stek
  • Brookie M Best
  • Intira Collins
  • Anchalee Singkaew
  • Praneet Pinklow
  • Guttiga Halue
  • Orapin Khatngam
  • Supawadee Tongsakulrungruang
  • Suppanut Khannak Jiradsadaporn Khanmali
  • Praornsuda Sukrakanchana
  • Den Roumsuk
  • Malee Techapornroong
  • Sirinat Toyang
  • Kantinan Leepaiboon
  • Parinee Suebchart
  • Sompong Wannun
  • Benjawan Thomyota
  • Panida Pongpunyayuen
  • Somsak Pattarakulwanich
  • Supattra Kaengklang
  • Chutima Seema
  • Nunthiya Phomcheam
  • Kesorn Jitmaleerat
  • Rungruangrong Seubmongkolchai
  • Benjaporn Juntapoon
  • Sinnapa Pothinukka
  • Pollawat Thongsuk
  • Parawan Bunditwong
  • Sunee Hanyutthapong
  • Wanpen Leelaporn
  • Wilai Raiva
  • Prateung Lianpongsabuddhi
  • Noupporn Jenpoomjai
  • Boonrak Wiriyachoke
  • Boonruen Pengmark

Detail Information

Publications8

  1. ncbi Early postpartum pharmacokinetics of lopinavir initiated intrapartum in Thai women
    Tim R Cressey
    Harvard School of Public Health, Boston, Massachusetts, USA
    Antimicrob Agents Chemother 53:2189-91. 2009
    ..2 (8.0 to 17.5) microg/ml, and 4.6 (1.7 to 12.5) microg/ml, respectively, at 41 (12 to 74) h after delivery. All of the women attained adequate LPV levels through 30 days postpartum. No serious adverse events were reported...
  2. ncbi Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum
    Tim R Cressey
    Program for HIV Prevention and Treatment IRD URI 174, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand
    J Acquir Immune Defic Syndr 59:245-52. 2012
    ..The impact of pregnancy on efavirenz (EFV) pharmacokinetics is unknown...
  3. ncbi Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1
    Tim R Cressey
    Harvard School of Public Health, Boston, MA, USA
    J Acquir Immune Defic Syndr 38:283-8. 2005
    ..To determine nevirapine (NVP) plasma levels during the postpartum period after a single intrapartum NVP dose for the prevention of mother-to-child transmission...
  4. ncbi Low-doses of indinavir boosted with ritonavir in HIV-infected Thai patients: pharmacokinetics, efficacy and tolerability
    Tim R Cressey
    Harvard School of Public Health, Harvard University, Boston, MA, USA
    J Antimicrob Chemother 55:1041-4. 2005
    ..To assess the steady-state pharmacokinetics of two reduced doses of indinavir boosted with ritonavir (indinavir/ritonavir) in HIV-infected Thai patients...
  5. ncbi Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: an update
    Tim R Cressey
    Harvard School of Public Health, Boston, MA, USA
    Infect Genet Evol 7:333-42. 2007
    ....
  6. ncbi Indinavir/ritonavir remains an important component of HAART for the treatment of HIV/AIDS, particularly in resource-limited settings
    Tim R Cressey
    Chiang Mai University, Program for HIV Prevention and Treatment PHPT IRD174, 29 7 8 Samlan Road, Soi 1 Prasing, Muang, Chiang Mai, 50205, Thailand
    Expert Opin Drug Metab Toxicol 3:347-61. 2007
    ..Similar low dosing levels in children have also proven successful, but data in pregnant women remains limited. Due to its low cost and proven efficacy indinavir remains a key component of HIV/AIDS treatment in resource-limited settings...
  7. ncbi Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy
    Tim R Cressey
    Department of Medical Technology, Chiang Mai University, Thailand
    AIDS 24:2193-200. 2010
    ....
  8. ncbi Influence of body weight on achieving indinavir concentrations within its therapeutic window in HIV-infected Thai patients receiving indinavir boosted with ritonavir
    Tim R Cressey
    Program for HIV Prevention and Treatment IRD URI 174, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand
    Ther Drug Monit 33:25-31. 2011
    ..The risk of toxic drug concentrations increases rapidly with IDV/r dose of 600/100 mg for patients less than 50 kg and therapeutic drug monitoring of IDV concentrations would help to reduce the risk of IDV-induced nephrotoxicity...